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SObjectives: Stereotactic body radiation therapy has been proposed as an alternative local treatment option for
high-risk patients with early-stage lung cancer. A direct comparison of outcomes between stereotactic body ra-
diation therapy and surgical resection has not been reported. This study compares short-term outcomes between
stereotactic body radiation therapy and surgical treatment of non–small cell lung cancer.
Methods: We compared all patients treated with surgery (January 2000–December 2006) or stereotactic body
radiation therapy (February 2004–May 2007) with clinical stage IA/B non–small cell lung cancer staged by com-
puted tomography and positron emission tomography. Comorbidity scores were recorded prospectively using the
Adult Co-Morbidity Evaluation scoring system. Charts were reviewed to determine local tumor recurrence,
disease-specific survival, and overall survival. A propensity score matching analysis was used to adjust estimated
treatment hazard ratios for confounding effects of patient age, comorbidity index, and clinical stage.
Results: A total of 462 patients underwent surgery and 76 received stereotactic body radiation therapy. Overall,
surgical patients were younger (P<.001), had lower comorbidity scores (P<.001), and better pulmonary func-
tion (forced expiratory volume in 1 second and carbon monoxide diffusion in the lung) (P< .001). Among the
surgical and stereotactic body radiation therapy groups, 62.6% (291/462) and 78.9% (60/76) were in clinical
stage IA, respectively. Final pathology upstaged 35% (161/462) of the surgery patients. In an unmatched com-
parison, overall 5-year survival was 55% with surgery, and the 3-year survival was 32% with radiation therapy.
Among patients with clinical stage IA disease, 3-year local tumor control was 89% with radiation therapy and
96% with surgery (P ¼ .04). There was no difference in local tumor control in stage IB disease (P ¼ .89). No
disease-specific survival differences were found in patients with 1A (P¼ .33) or IB disease (P¼ .69). Propensity
analysis matched 57 high-risk surgical patients to 57 patients undergoing stereotactic body radiation therapy. In
the matched comparison of this subgroup, there was no difference in freedom from local recurrence (88% vs
90%), disease-free survival (77% vs 86%), and overall survival (54% vs 38%) at 3 years.
Conclusions: In an unmatched comparison of clinical stage IA disease, surgical patients were healthier and had
better local tumor control compared with those receiving stereotactic body radiation therapy. Propensity analysis
in clinical stage IA/B non–small cell lung cancer revealed similar rates of local recurrence and disease-specific
survival in patients treated with surgery compared with stereotactic body radiation therapy. (J Thorac Cardiovasc
Surg 2010;140:377-86)Optimal management of very high-risk patients with early-
stage lung cancer remains a difficult challenge for the treat-
ing physician. Poor pulmonary function and cardiac-related
morbidity can limit the available treatment options. Al-
though it is speculated that mortality in these high-risk pa-
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The Journal of Thoracic and Capopulation-based studies have shown that when left un-
treated, patients with early-stage lung cancer die of their can-
cer, rather than of competing causes of death.1,2
Although surgical resection remains the standard of care
for early-stage lung cancer, new technology in radiation
therapy provides for more concentrated, focused therapy
that may improve efficacy and decrease toxicity compared
with traditional external beam radiation. Stereotactic radia-
tion therapy has been used for many years for the treatment
of intracranial lesions not amenable to surgical resection.
The application of this therapy has been extended to extra-
cranial tumors and is often referred to as stereotactic body
radiation therapy (SBRT). SBRT delivers high-dose radia-
tion over 3 to 5 treatment fractions using multiple conformal
coplanar and non-coplanar beams. This technique concen-
trates the prescribed radiation dose to the tumor morerdiovascular Surgery c Volume 140, Number 2 377
Abbreviations and Acronyms
ACE-27 ¼ Adult Co-Morbidity Evaluation-27
CT ¼ computed tomograph
FEV1 ¼ forced expiratory volume in 1 second
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
PSM ¼ propensity score matching
SBRT ¼ stereotactic body radiation therapy
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Sprecisely than conventional radiation therapy. Local tumor
control rates with SBRT range between 85% and 95% at
3 to 5 years.3-7 SBRT also limits the acute complications
frequently seen with external beam therapy.3-6 Severe
acute toxicity from SBRT ranges from 2% to 8% with
only 1 reported treatment-related death in several studies.5-7
Many prospective studies of SBRT in high-risk patients
have been reported, with 2-year survival ranging from
47% to 77%.3,4,7,8 Five-year survival has been reported as
36.5% to 47% with longer follow-up.3-7 Examining the
surgical experience in patients of varying risks, 5-year
survival for pathologic stage IA and IB disease is 73%
and 54%, respectively.9 For clinical stage IA and IB disease,
the 5-year survival is 50% and 40%, respectively.9 Al-
though prospective clinical trials are underway, there are
no direct comparisons of SBRT versus surgery in the man-
agement of early-stage lung cancer to date.
Our primary objective is to compare short-term outcomes
between patients undergoing primary treatment with SBRT
versus surgical resection for clinical stage I non–small cell
lung cancer (NSCLC) (T1 or T2 N0 M0) at our institution.
Propensity matched analysis enabled comparisons between
high-risk patients in the surgical group and patients receiv-
ing SBRT to examine survival in this subgroup.METHODS
All surgical patients with clinical stage I lung cancer treated between
January 1, 2000, and December 31, 2006, and all patients between February
1, 2004, and May 5, 2007, with clinical stage I lung cancer undergoing treat-
ment with SBRT were included and analyzed according to a protocol ap-
proved by our institutional review board. Not all patients receiving SBRT
in this study had pathologic diagnoses, although referral for a computed to-
mography (CT)-guided biopsy was requested in all patients. The patients
without a histologic diagnosis were considered to be too high of a risk for
pneumothorax by our inteventional radiologists. A biopsy was refused by
3 patients. In addition, all tumors in the SBRT group were nodular lesions
that were very suggestive of malignancy (ie, solid, spiculated) by CT or
demonstrated growth on serial CT scans. Each of these patients underwent
positron emission tomography–computed tomography (PET-CT) for stag-
ing. None had evidence of metastatic adenopathy and each of the lesions
subjected to SBRT was considered malignant. The very high-risk patients
undergoing SBRT did not routinely undergo staging mediastinoscopy or en-
dobronchial ultrasonography. Clinical staging was done with CT and PET
imaging in these patients. All CT scans and PET scans were reviewed in
the surgical group to include only those patients with clinical stage I lung378 The Journal of Thoracic and Cardiovascular Surgcancer. Comorbidity scores were recorded prospectively using the Adult
Co-Morbidity Evaluation (ACE-27) scoring system. Charts were reviewed
to determine local tumor recurrence, disease-specific survival, and overall
survival. Propensity score matching (PSM) was performed on the basis of
preoperative comorbidities and lung function. The ACE-27 form
(Appendix A) was used to stratify pretreatment comorbidity in both groups.
The comorbidity scores on all patients included in the trial were collected
prospectively from the Oncology Data Services database managed by the
Clinical Outcomes Research Office at Washington University. Exclusion
criteria include patients with small cell lung cancer or other cancers that
had metastasized to the lung, patients undergoing resection for benign dis-
ease, patients without preoperative staging chest CT and fluorodeoxyglu-
cose PET scans, patients with tumors graded T3 or greater, patients with
clinical N1 or N2 disease noted on preoperative imaging, and patients
with concurrent malignancy within the year before treatment. Data on pa-
tient demographics, history and physical examination, evaluation by chest
CT, fluorodeoxyglucose PET scans, operative report, and final pathology re-
ports (where available) were obtained from medical records.
In the surgical patients, the type of incision, type of resection (ie, lobar or
sublobar), and extent of lymph node dissection were at the discretion of the
treating surgeon. Patients undergoing SBRT were discussed at a multidisci-
plinary conference and were deemed to have inoperable disease by thoracic
surgeons unless the patient simply refused surgical intervention. Current
standard dosing delivers 54 Gy in 3 fractions over 8 to 14 days as currently
recommended by the Radiation Therapy Oncology Group. The SBRT de-
vice used in this study is the Trilogy system produced by Varian Medical
Systems, Inc (Palo Alto, Calif). This device does not generally require the
placement of fiducial markers. Each tumor is localized by cone-beam CT
on the Trilogy unit, axial, coronal, and sagittal alignment is matched to
the treatment plan, and therapy is delivered. In a few of our patients, fiducial
markers were placed to help clarify tumor position because of location near
the mediastinum or diaphragm. A total of 10 to 12 non-coplanar beams de-
liver the prescribed radiation dose to the periphery of the planning target
volume. The dose is typically prescribed to the 80% to 85% isodose line,
meaning that the center of the tumor received a dose that is 15% to 20%
higher than the prescription. Toxicity of SBRT was graded using the Na-
tional Cancer Institutes Common Toxicity Criteria version 3.0.
Statistical analysis was performed using SPSS 11.0 for Windows (SPSS,
Inc, Chicago, Ill) and Matlab (Mathworks, Inc, Natick, Mass). Descriptive
statistics such as mean and median were presented for continuous variables
whereas counts and proportions were presented for categorical data. Differ-
ences in mean were estimated by 2-tailed t test, in median using the Wil-
coxon rank sum, and in proportions using the c2 test. Multivariate
analysis of prognostic factors was performed using the Cox proportional
hazards model. Treatment groups matching based on selected covariates
was performed using PSM. In the PSM analysis, logistic regression was
used to estimate the corresponding scores from the baseline patient covari-
ates. To find matched patients from the 2 groups, we adopted a caliper
matching approach. In this approach, both treatment groups are randomly
sorted and then the datasets are matched using nearest neighbor distance
in terms of the propensity score that is within an acceptable distance, called
a ‘‘caliper.’’ This approach has the ability to avoid bad matches (too large
differences in propensity scores) compared with classic PSM methods.RESULTS
A total of 462 patients with clinical stage I disease met in-
clusion criteria and underwent surgical resection during the
defined study period whereas 76 underwent SBRT since the
institution of this technology. All patients among each treat-
ment group were clinically staged with CT and PET imag-
ing. Median follow-up in the SBRT and surgical groups
was 19 and 31 months, respectively.ery c August 2010
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FIGURE 1. A, Overall survival in surgically treated patients versus patients receiving SBRT for clinical stage I lung cancer. B, Disease-specific survival in
surgically treated patients and patients receiving SBRT for clinical stage I lung cancer. C, Local tumor control in surgically treated patients and patients re-
ceiving SBRT for clinical stage I lung cancer. SBRT, Stereotactic body radiation therapy; NSCLC, non–small cell lung cancer.
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SAmong the SBRT patients, 61 (80%) had biopsy-proven
disease before treatment, but 15 (20%) either refused biopsy
(n¼ 3) or were unable to undergo a biopsy (n¼ 12). In each
case the decisions to proceed with SBRT treatments in the
absence of tissue diagnoses were made in the context of
our multidisciplinary conference, which includes input
from surgeons, oncologists, radiation oncologists, and radi-
ologists. The average size of nodules lacking tissue diagno-
sis was 2.0 cm (median 1.8 cm), and 6 of 15 had documented
growth on serial CT scans. In addition, 14 of 15 patients
lacking histologic diagnosis had PET scans showing hyper-
metabolic nodules with a mean maximum standardized up-
take value of 6.3 (median 6.1). The remaining patient
without a PET scan had a known brain metastasis with ade-
nocarcinoma. In the SBRT group, there was no difference in
local control (P ¼ .3), disease-free survival (P ¼ .5), and
overall survival (P¼ .4) for patients who had a pretreatment
diagnosis versus those who did not.
The overall 5-year survival among patients with a diagno-
sis of clinical stage IA or IB NSCLC treated surgically in this
series was 55%. Owing to the lack of longer follow-up data
to adequately estimate 5-year survivals for the SBRT group,
3-year overall and disease-specific survivals were deter-
mined for both the surgery and SBRT groups. The overall
3-year survival for surgically treated patients was 68% com-
pared with a 3-year survival of 32% among patients receiv-
ing SBRT (Figure 1, A). The cancer-specific survival atThe Journal of Thoracic and Ca3 years was similar in both groups (82%) (Figure 1, B) Sim-
ilarly, there was no significant difference in local control at
3 years in patients treated with surgery (94%) versus SBRT
(89%) (P ¼ .13) (Figure 1, C).
In the unmatched comparison, patients with clinical stage
IA disease demonstrated no significant difference between
groups in disease-free survival (Figure 2, A). However, the
3-year local tumor control was 89% with SBRT and 96%
with surgery (P ¼ .04) in patients with clinical stage IA dis-
ease (Figure 2, B). There was no difference in either local tu-
mor control (91% vs 95%) or lung cancer–specific free
survival (75% vs 67%) among patients with stage IB dis-
ease between patients treated surgically and those receiving
SBRT, respectively (Figure 2, C and D).
Inasmuch as surgery is considered the standard of care for
patients with adequate lung function, and SBRT is reserved
predominantly for patients considered to be medically inop-
erable owing to cardiac or pulmonary comorbidities, the 2
treatment groups were not equally matched. As shown in
Table 1, surgically treated patients were younger
(P< .001), had lower comorbidity scores (P< .001), and
had better pulmonary function (forced expiratory volume
in 1 second [FEV1] and carbon monoxide diffusion in the
lung) (P< .001). Among the surgical and SBRT groups,
62.6% (291/462) and 75% (57/76) were in clinical stage
IA, respectively. The remaining patients in each group
were in clinical stage IB. Among patients treated withrdiovascular Surgery c Volume 140, Number 2 379
B 0
25
50
75
100
Time (Years)
Su
rv
iv
al
 (%
)
Stage IA -local control
p=0.04
Surgery (n=288)
SBRT (n=57)
A 0
25
50
75
100
Time (Years)
Su
rv
iv
al
 (%
)
p<0.33
Surgery (n=288)
SBRT (n=57)
Stage IA –NSCLC free survival
C 0
25
50
75
100
Time (Years)
Su
rv
iv
al
 (%
)
p<0.69
Surgery (n=174)
SBRT (n=19)
Stage IB –NSCLC free survival
D
0 1 2 3 4 50 1 2 3 4 5
0 1 2 3 4 5 0 1 2 3 4 5
0
25
50
75
100
Time (Years)
Su
rv
iv
al
 (%
)
Stage IB -local control
p=0.89
Surgery (n=174)
SBRT (n=19)
FIGURE 2. Disease-free survival and local tumor control in surgically treated patients versus patients receiving SBRT for clinical stage IA NSCLC (A and
B). Disease-free and local tumor control in surgical treated patients versus patients receiving SBRT for clinical stage IB NSCLC (C and D). SBRT, Stereotactic
body radiation therapy; NSCLC, non–small cell lung cancer.
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Ssurgery, the final pathology upstaged 35% of patients (161/
462). Sixty-four (13.8%) patients were found to have N1
disease with the final pathologic analysis and an additional
16 (3.5%) patients were found to have pathologic N2 dis-
ease. In addition, 43, 18, and 19 patients were upstaged to
pathologic T2, T3, and T4 tumors, respectively. In a single
patient, M1 disease was diagnosed by the identification of
synchronous tumor in a separate lobe at the time of surgery.
Pathologic upstaging by initial clinical stage is displayed in
Figure 3, A and B.
A multivariable Cox proportional hazards model was
used to adjust estimated treatment hazard ratios for con-
founding effects of patient age, comorbidity index, and clin-
ical stage. Table 2 outlines these results. In addition, because
of the significant differences in patient comorbidities noted
between patients treated surgically and patients who re-
ceived SBRT, propensity matching was performed to iden-
tify 2 similar groups of patients within the surgical and
SBRT treatment groups. These groups were matched with
regard to age, clinical stage, and ACE-27 comorbidity score,
which takes into account pulmonary function and cardiac
risk factors. Caliper-based PSM analyses were performed
to match surgical patients to the 76 patients who received
SBRT. Table 3 demonstrates the results of each analysis
based on different selections of the caliper parameter
(0.0005, 0.001, and 0.005), starting with most constringent380 The Journal of Thoracic and Cardiovascular Surgmatches and reducing the distance different constraint after-
ward. The acuity of the SBRT group made it difficult to
match surgical patients, thus the need for multiple analyses
to provide the reader with results at different levels of caliper
constraint. In the propensity matched comparison, there
were no differences in overall survival, disease-specific sur-
vival, or local control between the SBRT and surgery
groups, as shown in Figure 4, A, B, and C, for the most lib-
eral caliper selection of 0.005.
There were no treatment-related deaths associated with
SBRT. Complications associated with SBRT included grade
1 to 2 pneumonitis in 41 patients (51.9%) with only 1
(1.3%) patient experiencing grade 3 pneumonitis. Other mi-
nor complications with SBRT included 4 rib fractures, 3
pleural effusions, lung collapse in 2, hemoptysis in 1, and
bacterial pneumonia in 1. Among the 57 very high-risk sur-
gical patients identified in Figure 4, A to C, the operative
mortality was 7.0% (4/57) with complications affecting
43.8% of this subgroup (25/57). In this high-risk group, ar-
rhythmias accounted for 21% of complications and pneu-
monia/respiratory failure accounted for 27% all of
complications. Among the lower-risk surgical patients, the
operative mortality was 2.7% (11/405) with complications
occurring in 38.0% (154/405) of patients. In the low-risk
group, arrhythmias accounted for 22.7% of all complica-
tions, whereas pneumonia/respiratory failure accounted forery c August 2010
TABLE 1. Pretreatment and operative characteristics of surgically
treated patients and patients undergoing SBRT for clinical stage I
lung cancer
Variable
Surgery
(n ¼ 462)
SBRT
(n ¼ 76) P value
Age 66.7  9.8 (33–90) 75  10 (50–94) <.001
>75 y 97 (21%) 39 (51%) <.001
Male gender 34 (43%) 238 (52%) .19
T1 291 (62.6%) 57 (75%) .001
ACE score 2–3 171 (37%) 60 (79%) .001
FEV1% predicted 0.785 0.42 .001
DLCO% predicted 0.9 0.66 .001
Surgical procedure type
Wedge only 49
Lobectomy 322
Bilobectomy 19 N/A
Pneumonectomy 22 N/A
Wedgeþ lobectomy 24
Segmentectomy 16
Sleeve lobectomy 10
For dichotomous variables, count numbers are listed; P values are calculated using c2
statistics. For continuous variables, the median and range are listed, and P values are
calculated using the Mann–Whitney U test. ACE, Adult Co-Morbidity Evaluation;
FEV1, forced expiratory volume in 1 second; DLCO, carbon monoxide diffusion in
the lung; N/A, not applicable.
Clinical stage IA surgical patients
Final Pathological Stage 
200
150
100
50
0
Pa
tie
nt
s
A
IA IB IIA IIB IIIA IIIB IV
IA IB IIA IIB IIIA IIIB IV
Clinical stage IB surgical patients
Final Pathological Stage 
100
75
50
25
0
Pa
tie
nt
s
B
FIGURE 3. Pathologic stage of surgically treated patients among patients
with clinical stage IA (A) and stage IB (B) disease.
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S19.9%, atelectasis 10.4%, and prolonged air leaks (>7 days)
11.4%.
DISCUSSION
Surgical resection remains the gold standard for manage-
ment of patients with early-stage lung cancer. However, we
are often confronted with very high-risk patients secondary
to severe pulmonary dysfunction or other comorbid condi-
tions that make surgery prohibitive or, at the least, very haz-
ardous. This study was designed to identify the highest-risk
patients who underwent surgical resection and compare
them with patients undergoing treatment with SBRT. It is
important to note that the outcomes of patients analyzed in
the propensity matched groups included only surgical pa-
tients with the greatest surgical risk owing to diminished pul-
monary function and other comorbidities and that only
intermediate-term results are currently available. Extrapola-
tion of these results to healthier patients with a greater life
expectancy owing to their overall medical condition should
be done only with extreme caution. In the unmatched com-
parison, the local failure rate was higher in patients with
stage IA disease in the SBRT-treated group than in the sur-
gically treated group. Furthermore, surgical treatment al-
tered the pathologic stage in 35% of patients, affecting
both prognosis and potential adjuvant treatment. Although
there was no difference in local failure rates and disease-
specific survival in patients with stage IB disease, it is diffi-
cult to make conclusions because of the very small number
of patients in the SBRT group and the limited follow-up. Ex-The Journal of Thoracic and Catrapolation of data from the high-risk patients regarding the
efficacy of SBRT should not apply to patients with operable
disease outside of an approved clinical trial.
This study does emphasize the acuity of the population
being offered SBRT at our institution. There is a dramatic
difference in pulmonary function, age, and comorbidity be-
tween the groups. Attempts to match patients on the basis of
these parameters limited the number of surgical patients who
could be compared with the SBRT patients. In reality, a large
portion of the SBRT patients are simply patients who histor-
ically were not offered surgical treatment. Instead, these pa-
tients were likely treated with external beam radiation
therapy or were not treated at all.
Historical data regarding nonsurgical therapy reveal that
among untreated patients, lung cancer–specific 5-year sur-
vival has been reported as 23% for T1 lesions and 12%
for T2 lesions with an overall 5-year survival of 9% and
5%, respectively.2 Patients with stage I NSCLC treated
with conventional external beam radiation therapy have
overall and lung cancer–specific 5-year survivals of only
21%  8% and 25%  9%, respectively, in a review of
multiple trials.10 Radiofrequency ablation has beenrdiovascular Surgery c Volume 140, Number 2 381
TABLE 2. Cox regression analysis of all surgically treated patients and all patients undergoing SBRT for stage I NSCLC*
End point Surgery events SBRT events Hazard ratio (95% CI) P value
Local tumor control 22 (4.8%) 5 (6.3%) 0.47 (0.16–1.41 .182
Cause-specific survival 85 (18.4%) 12 (15.2%) 0.77 (0.40–1.48) .448
Overall survival 172 (37.2%) 41 (51.9%) 0.66 (0.43–0.92) .020
SBRT, Stereotactic body radiation therapy; NSCLC, non–small cell lung cancer; CI, confidence interval. *Using Cox proportional hazard model adjusted for age, comorbidity score,
and T stage.
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Sproposed as an alternative nonsurgical option for patients
with inoperable disease but has been associated with signif-
icant complications including pneumothoraces (28%–55%)
and hemoptysis.11-15 Furthermore, local progression after
radiofrequency ablation has been as high as 42% at 27
months for stage I NSCLC.12
Sublobar resections have been investigated in patients
with poor pulmonary function. The only prospective ran-
domized study comparing complete lobectomies to sublobar
resections failed to show any significant difference in long-TABLE 3. Matched cohort by propensity score matching
Variable Surgery SBRT P value
A. Matching using caliper radii of 0.0005 (n ¼ 23)
Age (y) 69 (47–82) 65 (51–89) .235
<75 y 17 18
75 y 6 5
Comorbidity score 1 (0–3) 2 (0–3) .562
0–1 13 10
2–3 10 13
T stage
T1 16 14 .536
T2 7 9
Others 0 0
B. Matching using a caliper radius of 0.001 (n ¼ 33)
Age (y) 69 (47–82) 68 (51–89) .376
<75 y 25 25
75 y 8 8
Comorbidity score 2 (0–3) 2 (0–3) .457
0–1 16 13
2–3 17 20
T stage
T1 22 21 .796
T2 11 12
Others 0 0
C. Matching using a caliper radius of 0.005 (n ¼ 57)
Age (y) 73 (47–90) 71 (50–94) .843
<75 y 37 34
75 y 20 23
Comorbidity score 2 (0–3) 2 (0–3) .310
0–1 20 15
2–3 37 42
T stage
T1 40 39 .839
T2 17 18
Others 0 0
SBRT, Stereotactic body radiation therapy. Logistic regression approach was used to
estimate probabilities of treatment assignment with age, comorbidity score, and T
stage as covariates.
382 The Journal of Thoracic and Cardiovascular Surgterm survival, but the local recurrence rate among patients in
the limited resection group was 3 times higher (6% vs
18%).16 More recently, segmentectomies have been shown
to have equivocal local control and long-term survival in el-
derly patients with NSCLC tumors less than 3.5 cm. More-
over, patients treated with sublobar resections in this study
had fewer complications.17 Sublobar resections have also
been offered to patients with compromised pulmonary func-
tion with or without brachytherapy in a randomized fashion.
Among 147 sublobar resections in high-risk patients for
stage I lung cancer, the local recurrence and regional recur-
rence rates were 7.2% and 6.8%, respectively.18 For pa-
tients with stage 1B disease, the addition of brachytherapy
to sublobar resection resulted in similar local recurrence
rates and disease-free survival at 4 years compared with
lobectomy.19 The mortality in the subgroup undergoing sub-
lobar resection and brachytherapy was 2.4% with a compli-
cation rate of 46%.19 By way of comparison, patients
undergoing brachytherapy/wedge resection in this study
had an average FEV1% of 52% to 53% compared with
our SBRT group, with a mean FEV1% of 42%.
19,20 This
emphasizes the fact that patients offered SBRT in our
study are at very high risk even compared with patients
currently being offered sublobar resection with or without
brachytherapy.
Although there has been no direct comparison with sur-
gery, there have been several studies examining SBRT in
high-risk patients. Onishi and associates5 have reported the
largest experience with the longest follow-up with a 5-year
overall survival of 47%, a local failure rate of 13.5%, and
a regional failure rate of 8.2%. Others have reported local
failure rates ranging from 3% to 16%.3,4,6-8,21 These
studies have demonstrated a survival advantage in stage I
lung cancer compared with no therapy or historical
controls of conventional external beam radiation therapy.
Our current results with SBRT are congruent with others
examining SBRT treatment in high-risk patients.
SBRT has been performed in high-risk patients with very
limited toxicity. Acute severe toxicity has been reported in
2% to 8% of treated patients and is manifest as severe pneu-
monitis, dermatitis, severe pain, or esophagitis.5-7 In this
study, minor (grade 1–2) acute pneumonitis occurred in
52% undergoing SBRT and was generally self-limited,
with grade 3 toxicity occurring in 1.3%. There has been
no severe late toxicity although our follow-up is short to
date. Overall, in the surgical group the operative mortalityery c August 2010
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Swas 3.2% (15/462) whereas the operative mortality in the
very high-risk surgical patients was 7.0% (4/57). This is
comparable with other large surgical series of lobectomy
among these groups of patients with lung cancer.22-24
Although this is the first report comparing an emerging
technology such as SBRT with surgery, this study is limited
by the relatively short follow-up period among patients re-
ceiving SBRT. There are few institutions in the United
States that have a large cohort of patients with long-term fol-
low-up to provide such a comparison. Although we have in-
cluded all patients with clinical stage I lung cancer receiving
SBRT, the short follow-up is a representative of our institu-
tion’s 4-year experience with this technology in treating
lung cancer. No SBRT patients in our series have been
lost to follow-up. The relative lack of long-term follow-up
reflects, in part, their underlying comorbidities, which limit
their survival. In light of this, analysis of local tumor control
and lung cancer–specific survival may skew the data in fa-
vor of SBRT. Owing to the medical comorbidities of the
SBRT patients, those dying of non–cancer related deaths
were counted as long-term lung cancer–specific survivors
with local control of their disease. Longer follow-up is
essential for adequate comparison of these groups and is
ongoing.
Another limitation in our study, as in other studies of non-
surgical therapy, is a discrepancy in the definitions of local
tumor control. Local control among patients treated surgi-The Journal of Thoracic and Cacally was defined as the lack of tumor recurrence within
the lung parenchyma or mediastinal lymph nodes. In con-
trast, local control among patients receiving SBRT was de-
fined as the lack of tumor progression radiographically in
the primary lobe. However, 3 (3.9%) of 76 patients receiv-
ing SBRT in our study had a recurrence within mediastinal
lymph nodes. Unlike these high-risk inoperable patients, tis-
sue confirmation of disease recurrence will be requisite in
clinical trials comparing SBRT with surgery in patients
that are fit for surgery.
The lack of preoperative surgical staging in the SBRT pa-
tients is also an important limitation of this study. Treatment
options were limited in these high-risk patients, and it was
often determined that surgical staging would not signifi-
cantly alter the treatment plan. Among operable and even
marginal patients, surgical staging with endobronchial ultra-
sonography or mediastinoscopy is essential both for progno-
sis and for treatment planning.
Treatment of these very high-risk patients with early-stage
lung cancer remains a challenge. Although some of these pa-
tients may undergo surgical treatment, many have comorbid
conditions that preclude surgical intervention. SBRT offers
a low-risk effective alternative to these patients with few
other options for treatment. Anticipated randomized trials
should help elucidate the relative role of SBRT in the treat-
ment armamentarium of early-stage lung cancer. SBRT
should not currently be recommended to patients withrdiovascular Surgery c Volume 140, Number 2 383
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pleted to support this approach.References
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